RedHill Biopharma (RDHL) Assets Average: 2013-2025
Historic Assets Average for RedHill Biopharma (RDHL) over the last 11 years, with Jun 2025 value amounting to $18.2 million.
- RedHill Biopharma's Assets Average fell 19.20% to $18.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was $18.2 million, marking a year-over-year decrease of 19.20%. This contributed to the annual value of $20.5 million for FY2024, which is 77.41% down from last year.
- Latest data reveals that RedHill Biopharma reported Assets Average of $18.2 million as of Q2 2025, which was down 9.11% from $20.0 million recorded in Q4 2024.
- In the past 5 years, RedHill Biopharma's Assets Average registered a high of $211.9 million during Q2 2021, and its lowest value of $18.2 million during Q2 2025.
- Over the past 3 years, RedHill Biopharma's median Assets Average value was $25.8 million (recorded in 2023), while the average stood at $40.9 million.
- In the last 5 years, RedHill Biopharma's Assets Average spiked by 84.01% in 2021 and then crashed by 81.62% in 2023.
- Quarterly analysis of 5 years shows RedHill Biopharma's Assets Average stood at $183.8 million in 2021, then dropped by 14.00% to $158.0 million in 2022, then tumbled by 81.62% to $29.0 million in 2023, then tumbled by 31.02% to $20.0 million in 2024, then dropped by 19.20% to $18.2 million in 2025.
- Its last three reported values are $18.2 million in Q2 2025, $20.0 million for Q4 2024, and $22.5 million during Q2 2024.